tbuckley/cabot-search huggingface dataset:
FRI0109 Are the rheumatoid arthritis patients treated with biologics with or without synthetic dmards in clinical practice different?
Authors: B. Hernández Cruz, R. Ariza Ariza, R. Caliz Caliz, E. Marquez Saavedra, F. Navarro Sarabia
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In clinical practice, about 30% of RA patients had comorbidities or drug intolerance that made difficult their treatment with Synthetic DMARDs in combination with biologics. <h3>Objectives</h3> To compare the characteristic of patients who were treated with commercial available biologic plus synthetic DMARDs vs. those patients treated with biologics without synthetic DMARDs. <h3>Methods</h3> Design: An observational, prospective cohort of patients with RA (ACR, 1987) attended in daily clinical practice. Setting: 17 Rheumatology Units of the Andalucian Service of Health. The Rheumatologist filled in a web page with clinical data for each patient at baseline and after 6 months of the first biologic. This data were saved and analiysed in a centralized way. This work was supported by the Central Services of the SAS and approved by the Autonomic Ethic Committee. <h3>Results</h3> From May, 2006 to March de 2010, 1.360 patients were included and 1.150 patients were analyzed. 238 (21%) were treated with biologic without synthetic DMARDs; 775 (67%) with biologic and one DMARD; 123 (11%) with biologic and two synthetic DMARDs; and 14 (1%) with biologic and three synthetic DMARDs. The main clinical characteristics are shown in the table. Patient treated with biologics without DMARDs were older and with longer RA duration; they had higher activity, as well as more comorbidity (hepatitis virus infection). Patient treated with biologic plus one synthetic DMARD had FR+ y/o Anti CCP+ more frequently, and nodular disease. Patients treated with biologics and ≥2 DMARDs were younger, with shorter disease duration. FR and/or Anti CCP were negative with higher frequency, and they had higher HAQ. The DAS at six months was similar in the groups. However, the HAQ improvement was different, regarding with the baseline HAQ. <h3>Conclusions</h3> The RA patients treated with biologics with or without synthetic DMARDS were different. However the response of DAS and HAQ improvement at six months was similar and clinically relevant in all groups. <h3>Disclosure of Interest</h3> B. Hernández Cruz Grant/research support from: From the Sociedad Andaluza de Reumatología, Employee of: FISEVI, R. Ariza Ariza: None Declared, R. Caliz Caliz: None Declared, E. Marquez Saavedra: None Declared, F. Navarro Sarabia: None Declared
Eculizumab for Atypical Hemolytic–Uremic Syndrome
Journal: New England Journal of Medicine (2009)

[CI], 0.57 to 0.83) for the first 21 days, 1.00 (95% CI, 0.57 to 1.76) for 22 to 60 days, and 0.38 (95% CI, 0.18 to 0.82) for 61 to 90 days. We also await results of trials such as POINT and TARDIS for confirmation of these results in non-Chinese populations. We agree with Jeong that there may be important differences according to the patients’ eth nicity and environment that limit the generalizability of our results, and we await the results of future clinical trials.
Antitubular Basement-Membrane Antibodies in Methicillin-Associated Interstitial Nephritis
Authors: Wayne A. Border, David H. Lehman, J. D. Egan, Hope J. Sass, John E. Glode, Curtis B. Wilson
Journal: New England Journal of Medicine (1974)

Abstract Antitubular basement-membrane antibodies were detected by indirect immunofluorescence in the serum of a patient in whom severe renal failure developed while he was receiving methicillin. A renal biopsy showed a severe mononuclear interstitial infiltrate with focal areas of tubular degeneration. IgG, C3 and a methicillin antigen assumed to be dimethoxyphenylpenicilloyl were present in a linear pattern along the tubular basement membrane but not along the glomerular basement membrane. The dimethoxyphenylpenicilloyl-tubular-basement-membrane hapten protein conjugate apparently led to an immune response with antitubular basement-membrane antibodies being involved in the immunopathogenesis of the patient's interstitial nephritis. (N Engl J Med 291:381–384, 1974)
Abstract 2649: Attenuation of JNK phosphorylation by 4-phenyl-3-butenoic acid in tumorigenic cells
Authors: Timothy J. Burns, Diane F. Matesic
Journal: Cancer Research (2011)

Abstract The c-Jun N-terminal kinase (JNK) signaling pathway controls many cellular processes such as cell growth, differentiation, and apoptosis. Aberrant JNK activity has been implicated in various cancer types including but not limited to hepatocellular carcinoma, glioblastoma, leukemia, and lung cancer, presumably through activation of the transcription factor activator protein-1 (AP-1). When activated by JNKs, AP-1 is a positive regulator of cell proliferation and many tumorigenic cell types are found to have increased JNK activity. Phosphorylated mitogen-activated protein kinase kinase 4 (pMKK4) and phosphorylated mitogen-activated protein kinase kinase 7 (pMKK7) are known to activate JNKs via phosphorylation. The purpose of this study was to determine the effects of 4-phenyl-3-butenoic acid (PBA) on JNK pathway proteins. PBA is a small molecule anti-inflammatory agent which was previously shown to inhibit growth, increase gap junction intercellular communication, and increase phosphorylation of p38 mitogen activated protein kinase (p38 MAPK) in tumorigenic cells at concentrations that do not similarly affect non-tumorigenic cells. Our studies utilized tumorigenic ras-transformed rat liver epithelial cells (WB-ras) and human lung carcinoma (H2009) cells. Cells were grown to confluence and were subjected to treatment with PBA (0.1 mg/ml) or vehicle for 48 hours. Whole cell lysates were extracted and individual proteins were separated by SDS-PAGE, followed by western blotting using phosphorylation site-specific antibodies to JNK pathway proteins. Quantitative analysis of western blots was performed utilizing densitometry software. PBA attenuated phosphorylation of JNK approximately two-fold in both WB-ras and H2009 lung carcinoma cells. PBA also attenuated phosphorylation of the JNK downstream effector, activating transcription factor 2 (ATF-2). Phosphorylation of MKK4 was decreased following treatment with PBA, while phosphorylation of MKK7 was unaffected. This data suggests that PBA may inhibit growth of tumorigenic cells in part through decreased activation of the JNK pathway via a MKK4 mechanism. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2649. doi:10.1158/1538-7445.AM2011-2649
PREOPERATIVE ANEMIA AND INTRAOPERATIVE TRANSFUSION TOGETHER PREDICT WORSENED SHORT AND LONG-TERM MORTALITY AFTER ISOLATED SURGICAL AORTIC VALVE REPLACEMENT
Authors: Surbhi Agrawal, Marc Najjar, Benjamin Ascherman, Deniz Akkoc, Samantha Stein, Sheetal Hegde, Catherine Wang, Paul Kurlansky, Michael Borger, Michael Argenziano, Craig Smith, Isaac George
Journal: Journal of the American College of Cardiology (2016)
P2-08-08: Benefit of Preoperative Breast MRI in Patients with Newly Diagnosed Breast Cancer.
Authors: M Miesbauer, H Sheu, A Schoissengeier, B Kirchweger, P Waldenberger
Journal: Cancer Research (2011)

Abstract Objective: The aim of our study was to evaluate the effect of routinely performed preoperative Breast MRI (pMRI) on the planned therapeutical management of all patients with newly diagnosed Breast cancer. Subjects and Methods: 180 patients with newly diagnosed Breast Cancer between 9/2009 - 12/2010 were enrolled in this retrospective study performed in a certified European Breast Cancer Unit; mean age 60,6 years; 1,5 T MRI ( TIM-Symphony, Siemens Germany). Results: In 53/180 (29,4%) cases the preoperative MRI changed the planned therapeutical management concerning surgical and chemotherapeutical options. In 42/180(23,3%) patients additional lesions were identified only by pMRI, 33/42(78,6%) have been malignant and 8/42(19%) were benign. The real extent of the tumor was detected in 43/53 (81%) cases — group A; a bilateral carcinoma was detected in 4/53 (7,5%) cases — group B; in 6/53 (11,5%) cases the malignant lesion could only be detected with preoperative MRI — group C; for group A the pMRI led to wider excisions with 15 segmental -or quadrant resections and 28 mastectomies; for group B the pMRI resulted in 4 additional lumpectomies; for group C the pMRI caused 4 lumpectomies, 1 segemental resection and 2 mastecomies .5 of 6 patients got neoadjuvant chemotherapy only due to results of pMRI; in 3 of these 5 patiens breast conserving surgery was possible. Histology: DCIS 23/53 (43,4%), invasive cancer 23/53 (43,4%), multicentric/multifocal malignant lesions 7/53 (13,2%). The sensitivity of the pMRI was not influenced by the histology of the lesion, the age of the patient or menopausal status. The maximum periode between initial presentation of the patient and breast surgery was 21 days. Conclusion: In 29,4% of our patients the pMRI resulted in a significant change of the planned therapeutical regime. Histology of the lesion, patients age or menopausal status did not influence the sensitivity of pMRI. There was no relevant delay in the initiation of treatment. Therefore we recommend performing pMRI in breast cancer staging routinely. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-08-08.
MAJOR VASCULAR COMPLICATIONS AFTER TRANSFEMORAL TAVI: INCIDENCE AND IMPACT ON 30-DAY MORTALITY ACCORDING TO VARC-1 AND VARC-2 DEFINITIONS
Authors: Joseph Nader, Eric Durand, Carlos Rodriguez, Guillaume Avinee, Guillaume Cellier, Matthieu Godin, Christophe Tron, G. Alain Cribier, Helene Eltchaninoff
Journal: Journal of the American College of Cardiology (2015)
Newly designed, fully covered metal stents for endoscopic ultrasound (EUS)-guided transmural drainage of peripancreatic fluid collections: a prospective randomized study
Authors: Byung Lee, Tae Song, Sang Lee, Do Park, Dong-Wan Seo, Sung-Koo Lee, Myung-Hwan Kim
Journal: Endoscopy (2014)

Peripancreatic fluid collections (PFCs) have been adequately drained using multiple plastic stents placed in a single-step endoscopic ultrasound (EUS) procedure. Recent reports have presented the usefulness of metal stents for this procedure; however, there has been no prospective comparative study on their effectiveness and safety. We conducted a prospective randomized study to compare multiple plastic stents with fully covered, self-expanding metal stents (FCSEMSs) for the drainage of PFCs.Between January 2012 and May 2013, patients with PFCs demonstrated by various modalities were enrolled in our study. Patients were randomly assigned to receive either a FCSEMS or plastic stents for EUS-guided PFC drainage. The procedure time, technical success rate, and adverse event rates of the PFCs were evaluated.50 patients (41 men) were included and randomly assigned to either the FCSEMS group (n = 25) or the plastic stent group (n = 25). The median procedure time with FCSEMS was significantly shorter than with plastic stents (15.0 min vs. 29.5 min, P < 0.01). The technical success rate was 100 % for both groups. The clinical success rate was 20 out of 23 for FCSEMS and 20 out of 22 for plastic stents (P = 0.97). No adverse events occurred in the FCSEMS group, while adverse events occurred in two patients in the plastic stent group (P = 0.16). One recurrence was observed during follow-up in the FCSEMS group and none in the plastic stent group (P = 0.15).EUS-guided PFC drainage with FCSEMSs is comparable to such drainage with plastic stents in terms of technical feasibility, efficacy, and safety; however, the use of FCSEMSs may also simplify and shorten the procedure.KCT0000766 (https://cris.nih.go.kr).
RECURRENT HYPOTENSION DURING HEMODIALYSIS ASSOCIATED WITH DOUBLE-CHAMBERED RIGHT VENTRICLE IN HYPERTROPHIC CARDIOMYOPATHY PATIENT
Authors: Kyu-Hwan Park, Chan-Hee Lee, Yoon-Jung Choi, Kang-Un Choi, Jang-Won Son, Ung Kim, Jong-Seon Park, Dong-Gu Shin, Young-Jo Kim
Journal: Journal of the American College of Cardiology (2015)
THU0062 Course and Outcome of Uveitis in Patients with Ankylosing Spondylitis: Table 1.
Authors: A. Godzenko, A. Bochkova, O. Rumyantseva, I. Razumova, S. Erdes
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Uveitis is most common extraskeletal manifestation of ankylosing spondylitis (AS). In accordance with traditional views, uveitis within AS characterized by favourable course and rarely leads to impaired vision. <h3>Objectives</h3> To assess clinical course and complications of uveitis in AS pts. <h3>Methods</h3> Sectional study of 140 AS pts (98 men and 42 women) with at least one episode of uveitis during disease. In addition to standard rheumatological examination, all pts were examined by ophthalmologist using ophtalmoscopy, biomicroscopy, tonometry, computer perimetry, ultrasonic scanning, as needed - fluorescein angiography and electrophysiological studies of the retina for detection of settings and complications of uveitis. Total number of uveitis flares until study and the average number of flares per year were calculated for each pt. <h3>Results</h3> 136 (97%) pts had HLA-B27, 43 (30%) - peripheral arthritis, 46 (32%) – other extrasceletal manifestations. Onset of uveitis before manifestation of AS had 37 (26,4%) pts, during first 10 years of AS - 81 (58%), after 10 years of AS – 21 (15%). 33 (24%) had more then 10 episodes of uveitis during diseas and 34 (24,5%) had more then 2 flares per year, 18 (13%) had chronic course of uveitis with persisting of inflammation longer than 3 month. Isolated iridocyclitis was found in 118 (84%)pts, panuveitis – in 12 (8%), separate posterior uveitis – in 2 (0,01%). 122 (87%) pts had unilateral uveitis, 18 (13%) – bilateral, 45 (36%) had alternate eye attacks (D-S). Complications that led to decrease of vision was found in 41 (29%) pts: synechia – in 26 (18%), vitreous body destruction – in 20 (14%), cataract – in 32 (23%), glaucoma – in 13 (9%), maculopathy - in 6 (4%), band keratopathy - in 6 (4%), optic atrophy –in 3 (2%). Direct correlation was found between frequency of uveitis flares and development of complications (Table 1). <h3>Conclusions</h3> Uveitis within AS characterized by onset predominantly during first 10 year of disease, prevalent unilateral iridocyclitis, recurrent course. Approximately 1|3 of pts have complications with decrese of vision that correlate with frequency of uveitis flares. <h3>References</h3> Feltkamp T.E.W, Ringrose J. Acute anterior uveitis and spondyloarthropathies. Current Opinion in Rheumatology, 1998, 10: 314-318 Goueia E., Elmann D. Ankylosing spondylitis and uveitis: overview, Bras Rheumatol. 2012; 52: 5 <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2607
Genetic, phenotypic and clinical features of acute lymphoblastic leukemias expressing myeloperoxidase mRNA detected by RT-PCR
Authors: J Serrano, J Román, A Jiménez, JA Castillejo, JA Navarro, J Sánchez, JM García-Castellanos, C Martín, J Maldonado, A Torres
Journal: Leukemia (1999)
Colonoscopy by nurse endoscopists: the right answer for the growing demand for colonoscopy in clinical practice?
Authors: A. Tursi
Journal: Endoscopy (2013)

In their recent study, van Putten and colleagues reported the Dutch experience of nurse endoscopists in performing colonoscopies. They reported that adherence to international standards and patient satisfaction were very high, and most of the patients had no specific preference for a physician or a nurse endoscopist [1]. Although I find this report interesting, I cannot entirely share its conclusions, and feel that some comment is needed.
123 STRUCTURE OF THE HEPATITIS B VIRUS RNase H, A TARGET FOR NEW ANTIVIRAL DRUG DEVELOPMENT, UNRAVELED BY ULTRA-DEEP PYROSEQUENCING AND MOLECULAR MODELING
Authors: J. Hayer, C. Rodriguez, G. Germanidis, G. Deleage, F. Zoulim, J.-M. Pawlotsky, C. Combet
Journal: Journal of Hepatology (2013)
PATIENTS ON HEMODIALYSIS HAVE WORSE OUTCOMES COMPARED WITH NON-DIALYSIS PATIENTS AFTER SUBCUTANEOUS IMPLANTABLE-CARDIOVERTER DEFIBRILLATOR IMPLANTATION
Authors: Eduard Koman, Ashwani Gupta, Faiz Subzposh, Ankur Tiwari, John Fontaine, Slawomir Kusmirek, Heath Saltzman, Steven Kutalek
Journal: Journal of the American College of Cardiology (2015)
Abstract 1561: An evaluation of the use of genetically modified mouse models in human cancer risk assessment.
Authors: David A. Eastmond, Suryanarayana V. Vulimiri, John E. French, Babasaheb Sonawane
Journal: Cancer Research (2013)

Abstract The development of short-term or accelerated cancer bioassays using genetically modified (GM) animals that exhibit high sensitivity to chemically induced cancers and that act through mode(s) of action relevant to humans continues to be an important focus of research. However, to date only a few GM mouse models such as the Trp53+/−, the Tg.AC and the rasH2 models have effectively been evaluated to substitute for the two-year rodent cancer bioassays. Whether these models provide an acceptable replacement for the conventional rodent cancer bioassay for assessing human cancer risks is the subject of ongoing debate. The objective of this study was to evaluate the current status of the use of GM mice for accelerated cancer bioassays in assessing the potential human health risks associated with exposure to carcinogenic agents. We compared the published data from the GM bioassays with results obtained using the National Toxicology Program's conventional 2-year mouse cancer bioassay presently used in human cancer risk assessment. The results demonstrate a moderate success for these GM models to distinguish carcinogens from non-carcinogens. Although the GM models are less efficient in detecting rodent carcinogens, they are more consistent in identifying non-carcinogens. Our analysis also shows that there continue to be concerns about the assay design and protocols used for the GM models, including issues related to sample size, study duration, genetic instability, and reproducibility. Additional issues of concern include specific toxicity pathway-dependent effects, and differences in the potential carcinogenic mechanisms operating in GM and non-GM animals, topics that still need to be investigated. In addition, the dose-responses of the GM models can vary substantially from those seen in conventional cancer bioassays. Overall, we conclude that the existing GM mouse models are of value for hazard identification, but are of limited use for dose-response analysis with currently used study designs. Hence, until these models are thoroughly validated using more robust study designs and the dose-response issues adequately addressed, caution should be exercised when using the current GM models to assess the carcinogenic risks of chemicals to humans. Disclaimer: The views expressed in this abstract are those of the authors and do not necessarily reflect the views or policies of the U.S. Environmental Protection Agency or the National Institute of Environmental Health Sciences. Citation Format: David A. Eastmond, Suryanarayana V. Vulimiri, John E. French, Babasaheb Sonawane. An evaluation of the use of genetically modified mouse models in human cancer risk assessment. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1561. doi:10.1158/1538-7445.AM2013-1561
Financial Strain and Cancer Outcomes
Authors: Robert M. Kaplan, Arnold Milstein
Journal: Journal of Clinical Oncology (2016)

nationally representative Cancer Care Outcomes Research and Surveillance Consortium study to suggest that limited financial reserves are associated with greater symptom burden and reduced qualityof life among patients with comparable clinical stages of lung or colorectal cancer. Using multivariable analysis, the authors attempted to rule out alternative explanations, including age, race/ethnicity, sex, income, health insurance status, cancer stage, and the presence of other chronic illnesses. The results complement a growing literature that documents
P166 A COACH, A PLAYMAKER, A DEFENDER AND STRIKERS: AN EPIGENETIC-TARGET INTERPLAY IN HCV/HCC
Authors: M.M. Fouad, N.M. Elemam, H.B. Sherif, S.A. El Sobky, R.A. Yacoub, A.K. Abelhamid, T. Elbaz, M.A. Mohey El Din, I.O. Fawzy, H.M. El Tayebi, N. El-Ekiaby, R.Y. Mekky, G. Esmat, A.I. Abdelaziz
Journal: Journal of Hepatology (2014)
PTU-066 New Insight into the Mucosal Profile of Eicosanoid Mediators in Ulcerative Colitis
Authors: D S Pearl, M Masoodi, M Eiden, J K Shute, P C Calder, T M Trebble
Journal: Gut (2013)

<h3>Introduction</h3> Ulcerative colitis (UC) is a relapsing remitting disorder of the colon with a recognised role for certain eicosanoid mediators derived from polyunsaturated lipid substrates. However, a detailed characterisation of the eicosanoids involved in UC is currently lacking. Using a comprehensive lipidomics approach, we profiled eicosanoids that could exhibit both pro- and anti-inflammatory function in inflamed and non-inflamed colonic mucosal biopsies from UC patients. <h3>Methods</h3> Biopsies were taken from inflamed and nearby non-inflamed colonic mucosa (69 patients, 54 with paired inflamed and non-inflamed mucosa) from patients with symptomatic relapses. Inflammation was scored endoscopically and histologically. Mucosal lipid mediators were determined by LC-MS/MS lipidomics analysis. Univariate and multivariate statistical analyses were used to investigate the association of lipid mediators with the disease state as well as histologically assessed disease severity (using the Gomes scoring system). <h3>Results</h3> Arachidonic acid (AA), but not eicosapentaenoic acid (EPA), derived eicosanoids (prostaglandin (PG)E2, PGD2, thromboxaneB2, 5-hydroxy-eicosatetraenoic acid (HETE), 11-HETE, 12-HETE and 15-HETE), were significantly (p &lt; 0.001) higher in inflamed than non-inflamed mucosa and their concentrations correlated to histological severity. <h3>Conclusion</h3> There is an upregulation of AA derived inflammatory mediators in UC. This research suggests new eicosanoid targets for research and therapeutic intervention. <h3>Disclosure of Interest</h3> None Declared